ClinicalTrials.gg
RecruitingNCT07717567BLADUpdated Jul 21, 2026

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression

An observational study in Alzheimer Disease, Mild Cognitive Impairment and Subjective Cognitive Decline, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.

Started
2023
with 1 other
Observational
6 of 10
4 open now
Registered
9th of 10
by date

Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 9th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alzheimer Disease by IRCCS San Raffaele, or all of them as a file.
02

Study summary

BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.

2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.

The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.

Read the detailed description

In light of the possible advent of disease-modifying drugs for Alzheimer's disease (AD), reliable biomarkers have been developed in recent years to define the presence of AD pathology at the brain level. The current biological gold standards are cerebrospinal fluid (CSF) biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) and amyloid-PET. Both methods have excellent diagnostic properties but are costly and invasive, limiting their use outside of highly specialized centers.

Plasma biomarkers (plasma-Abeta40, plasma-Abeta42, plasma-pTau-181, plasma-NfL, plasma-ApoE, plasma-ApoE4, plasma-GFAP, plasma-sTREM2, and other plasma neurodegeneration biomarkers) represent a potentially less invasive and more economically accessible alternative. Recent studies have shown that plasma biomarkers can differentiate AD from other neurodegenerative disorders with accuracy comparable to CSF and PET, detect AD pathology in MCI patients, and predict future development of AD dementia in patients with SCD or MCI. However, more research is needed before their widespread use in clinical practice.

The BLAD study is designed as a monocentric, prospective, observational epidemiological study with an additional procedure (annual blood draw for 5 years) and a diagnostic accuracy sub-study (not device-based).

Patients will be recruited among those attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital during routine clinical practice. All enrolled patients will undergo annual blood sampling for 5 years in addition to standard clinical assessments.

A sub-population of 150 patients who undergo lumbar puncture as part of their routine diagnostic workup will enter the validation sub-study. Only those whose CSF biomarkers confirm a biological diagnosis of Alzheimer's disease will continue follow-up; others will exit the sub-study.

The equipment for plasma biomarker measurement (CE-marked medical device) and laboratory kits will be provided on free loan by Fujirebio. No clinical or laboratory data will be shared with Fujirebio.

Statistical analyses will include: log-rank test to compare time to AD development between groups above and below the biomarker threshold; linear stepwise regression models, linear mixed-effects models, and multivariable Cox models to assess the prognostic value of plasma biomarkers; longitudinal generalized linear models for repeated measures or Wilcoxon test to assess biomarker dynamics over time. For the validation sub-study, ROC curve analysis will be performed to assess accuracy, sensitivity, and specificity of plasma biomarkers against CSF gold standard.

03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Subjective Cognitive Decline
  • Dementia
  • Cognitive Impairment

Keywords

  • Alzheimer's disease
  • Plasma biomarkers
  • pTau-181
  • Abeta42
  • Abeta40
  • NfL
  • GFAP
  • sTREM2
  • ApoE
  • Mild Cognitive Impairment
  • Subjective Cognitive Decline
  • Dementia
  • Blood biomarkers
  • Diagnostic accuracy
  • Prognosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy, presenting with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature.

Eligibility criteria

Inclusion Criteria (main study and sub-study):

  1. Age greater than or equal to 40 years (patients of childbearing age are admitted).
  2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.
  3. (MMSE) score greater than or equal to 18.

    Additional inclusion criterion for the validation sub-study:

  4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.

Exclusion Criteria (main study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy or breastfeeding.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who require a legal guardian or tutor.

Exclusion Criteria (validation sub-study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who are unable to give and require a legal guardian or tutor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Main Study Cohort

    2000 adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature. All patients undergo annual blood sampling for 5 years in addition to standard clinical follow-up.

    Procedure: Annual blood draw for plasma biomarker measurement

  • Validation Sub-study Cohort

    150 patients from the main cohort who undergo lumbar puncture as part of their routine diagnostic workup and have CSF biomarkers for Alzheimer's disease available within 6 months of blood draw. Only those with CSF biomarkers confirming a biological diagnosis of Alzheimer's disease continue longitudinal follow-up in the sub-study.

    Procedure: Annual blood draw for plasma biomarker measurement

Interventions

  • ProcedureAnnual blood draw for plasma biomarker measurement

    A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.

06

What researchers measure

Primary outcomes

  1. Time to progression to all-cause dementia in MCI patients (primary prognostic endpoint)

    Time to clinical progression to all-cause dementia in patients with Mild Cognitive Impairment (MCI) at baseline, assessed using multivariable Cox proportional hazards models. For each plasma biomarker, patients are divided into two groups (above/below the median) and compared using the log-rank test (cause-specific hazard). The study has greater than 95% power to detect a Hazard Ratio of 2 and approximately 75-80% power for HR of 1.5.

    Time frame: Annually from baseline up to 5 years

Secondary outcomes

  1. Change in MMSE score over time

    Change over time in Mini-Mental State Examination (MMSE) score as a measure of cognitive progression. A decrease of 5 or more points is considered clinically significant progression of cognitive impairment due to AD.

    Time frame: Annually from baseline up to 5 years

  2. Conversion from MCI to Alzheimer's disease dementia

    Rate of clinical conversion from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia over the 5-year follow-up period, assessed at each annual visit.

    Time frame: Annually from baseline up to 5 years

  3. Longitudinal change in plasma Abeta42/Abeta40 ratio

    Change over time in the plasma Abeta42/Abeta40 ratio, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  4. Longitudinal change in plasma pTau-181 levels

    Change over time in plasma phosphorylated tau 181 (pTau-181) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  5. Longitudinal change in plasma NfL levels

    Change over time in plasma neurofilament light chain (NfL) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  6. Longitudinal change in plasma GFAP levels

    Change over time in plasma Glial Fibrillary Acidic Protein (GFAP) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  7. Longitudinal change in plasma sTREM2 levels

    Change over time in plasma soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  8. Longitudinal change in plasma Abeta40 levels

    Change over time in plasma beta-amyloid 40 (Abeta40) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

  9. Longitudinal change in plasma Abeta42 levels

    Change over time in plasma beta-amyloid 42 (Abeta42) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.

    Time frame: Annually from baseline up to 5 years

Other outcomes

  1. Diagnostic accuracy of plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)

    Area under the ROC curve (AUC), sensitivity, and specificity of plasma Abeta42/Abeta40 ratio in diagnosing Alzheimer's disease, using CSF biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) as the gold standard. Patients are classified as AD or non-AD based on CSF results. An AUC of at least 0.80 is expected, with greater than 95% power to reject H0: AUC=0.50 at alpha=0.05.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  2. Diagnostic accuracy of plasma pTau-181 vs CSF gold standard (sub-study)

    Area under the ROC curve (AUC), sensitivity, and specificity of plasma pTau-181 in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  3. Diagnostic accuracy of plasma NfL vs CSF gold standard (sub-study)

    Area under the ROC curve (AUC), sensitivity, and specificity of plasma NfL in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  4. Diagnostic accuracy of plasma GFAP vs CSF gold standard (sub-study)

    Area under the ROC curve (AUC), sensitivity, and specificity of plasma GFAP in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  5. Optimal diagnostic cut-off values for plasma Abeta40 vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for Abeta40 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  6. Optimal diagnostic cut-off values for plasma Abeta42 vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for Abeta42 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  7. Optimal diagnostic cut-off values for plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for Abeta42/Abeta40 ratio biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  8. Optimal diagnostic cut-off values for plasma pTau-181 vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for pTau-181 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  9. Optimal diagnostic cut-off values for plasma NfL vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for NfL biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  10. Optimal diagnostic cut-off values for plasma GFAP vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for GFAP biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  11. Optimal diagnostic cut-off values for plasma sTREM2 vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for sTREM2 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  12. Optimal diagnostic cut-off values for plasma ApoE vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for ApoE biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

  13. Optimal diagnostic cut-off values for plasma ApoE4 vs CSF gold standard (sub-study)

    Determination of the optimal diagnostic cut-off values for ApoE4 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.

    Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)

07

Study locations

1 of 1 sites recruiting
  • IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD)
    Milan, Milano 20132, Italy
    Recruiting
    • Federica Agosta, MD · Contactagosta.federica@hsr.it · 0226433051
    • Giuseppe Magnani, MD · Contact
    • Massimo Filippi, Prof, MD · Principal investigator
    • Federica Agosta, MD · Sub investigator
    • Giuseppe Magnani, MD · Sub investigator
    • Giordano Cecchetti, MD · Sub investigator
    • Francesca Caso, MD · Sub investigator
    • Roberto Santangelo, MD · Sub investigator
    • Gioele Spinelli, MD · Sub investigator
    • Giulia Rugarli, MD · Sub investigator
    • Federico Coraglia, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jun 2032, 104 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 104 months is above that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Sep 12, 2023
Primary completionEst.
Jun 1, 2032
CompletionEst.
Jun 1, 2032
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717567
Lead sponsor
IRCCS San Raffaele
Responsible party
Prof. Massimo Filippi (Prof, MD, IRCCS San Raffaele) — Principal investigator
First posted
Jul 21, 2026
Start date
Sep 12, 2023
Primary completion
Jun 1, 2032 (estimated)
Completion
Jun 1, 2032 (estimated)
Last update
Jul 21, 2026

Study contacts

Federica Agosta, MD
Contact
agosta.federica@hsr.it
0226433051
Giuseppe Magnani, MD
Contact
Massimo Filippi, Prof, MD
principal investigator · IRCCS San Raffaele

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion